Piper Sandler Increases Replimune Group (NASDAQ:REPL) Price Target to $22.00

Replimune Group (NASDAQ:REPL) had its target price lifted by equities researchers at Piper Sandler from $14.00 to $22.00 in a report released on Monday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Piper Sandler’s price target suggests a potential upside of 128.45% from the stock’s current price.

Other analysts also recently issued research reports about the stock. HC Wainwright raised their price target on shares of Replimune Group from $21.00 to $22.00 and gave the stock a “buy” rating in a research report on Thursday, February 13th. JPMorgan Chase & Co. raised their price target on shares of Replimune Group from $16.00 to $18.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 26th. Eight research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Replimune Group presently has a consensus rating of “Buy” and an average price target of $19.75.

Replimune Group Stock Up 0.6%

REPL stock opened at $9.63 on Monday. Replimune Group has a twelve month low of $4.93 and a twelve month high of $17.00. The company has a current ratio of 11.43, a quick ratio of 11.43 and a debt-to-equity ratio of 0.14. The company has a market capitalization of $742.35 million, a P/E ratio of -3.14 and a beta of 0.68. The firm has a 50 day simple moving average of $8.35 and a 200-day simple moving average of $11.06.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings results on Thursday, May 22nd. The company reported ($0.82) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.07). During the same period last year, the business earned ($0.25) EPS. On average, equities research analysts predict that Replimune Group will post -2.97 earnings per share for the current fiscal year.

Insider Buying and Selling at Replimune Group

In other Replimune Group news, insider Christopher Sarchi sold 3,749 shares of the firm’s stock in a transaction on Tuesday, May 20th. The stock was sold at an average price of $8.05, for a total value of $30,179.45. Following the sale, the insider now directly owns 128,296 shares in the company, valued at approximately $1,032,782.80. This trade represents a 2.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Konstantinos Xynos sold 7,952 shares of the firm’s stock in a transaction on Tuesday, May 20th. The shares were sold at an average price of $8.06, for a total value of $64,093.12. Following the completion of the sale, the insider now owns 146,933 shares in the company, valued at $1,184,279.98. The trade was a 5.13% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 74,907 shares of company stock worth $603,655. 8.80% of the stock is owned by insiders.

Institutional Investors Weigh In On Replimune Group

A number of hedge funds have recently added to or reduced their stakes in REPL. SG Americas Securities LLC lifted its stake in Replimune Group by 14.7% in the fourth quarter. SG Americas Securities LLC now owns 26,291 shares of the company’s stock valued at $318,000 after buying an additional 3,374 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its stake in shares of Replimune Group by 24.2% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 16,317 shares of the company’s stock valued at $198,000 after purchasing an additional 3,177 shares in the last quarter. Rhumbline Advisers lifted its holdings in Replimune Group by 8.3% in the fourth quarter. Rhumbline Advisers now owns 95,465 shares of the company’s stock worth $1,156,000 after purchasing an additional 7,317 shares during the period. New York State Common Retirement Fund lifted its holdings in Replimune Group by 260.8% in the fourth quarter. New York State Common Retirement Fund now owns 43,204 shares of the company’s stock worth $523,000 after purchasing an additional 31,231 shares during the period. Finally, Bank of New York Mellon Corp lifted its holdings in Replimune Group by 7.3% in the fourth quarter. Bank of New York Mellon Corp now owns 174,518 shares of the company’s stock worth $2,113,000 after purchasing an additional 11,893 shares during the period. 92.53% of the stock is currently owned by institutional investors.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.